GenSight Biologics Announces Regulatory Authorizations for Individual Patient Expanded Access Treatment with GS010/LUMEVOQ® in the US

Core Insights - GenSight Biologics has received regulatory authorizations for its gene therapy GS010/LUMEVOQ® for Individual Patient Expanded Access in the United States [1] Company Summary - GenSight Biologics is a biopharma company focused on developing and commercializing innovative gene therapies specifically for retinal neurodegenerative diseases and central nervous system disorders [1]